Tamer Fandy

Prof. Tamer Fandy

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021
Verified
Book Chapter
Closed access
GUGias Uddin
Gias Uddin
Tamer FandyTamer Fandy
Tamer Fandy

4 September 2014 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
HHHazem E. Hassan
Hazem E. Hassan
SCSamuel Carlson
Samuel Carlson
IAInas Abdallah
Inas Abdallah
TBThomm Buttolph
Thomm Buttolph
KGKaren C. Glass
Karen C. Glass
Tamer FandyTamer Fandy
Tamer Fandy

1 August 2015 in Journal of Biomedical Informatics
Verified
Journal Article
Closed access
AHAhmed Abdeen Hamed
Ahmed Abdeen Hamed
XWXindong Wu
Xindong Wu
RERobert Erickson
Robert Erickson
Tamer FandyTamer Fandy
Tamer Fandy

12 January 2026 in Cells
Verified
Journal Article
Open access
PDF file
JTJonathan Trejo
Jonathan Trejo
HKHayes Koegeboehn
Hayes Koegeboehn
FFFarah Faizuddin
Farah Faizuddin
RLRyan Patrick Logan
Ryan Patrick Logan
MTMichel Toutoungy
Michel Toutoungy
JCJessica A Chacon
Jessica A Chacon
The intricate interplay between the human microbiota and the immune system has garnered significant attention in recent years, particularly concerning its implications in cancer biology. Macrophages, pivotal players in the tumor microenvironment (TME), exhibit diverse phenotypes that can either promote tumor progression or inhibit it. This review explores the multifaceted role of the microbiota in modulating macrophage polarization within the TME. We highlight recent findings that demonstrate how specific microbial communities influence macrophage behavior through metabolic pathways, immune signaling, and epigenetic modifications. Furthermore, we discuss the therapeutic potential of manipulating the microbiota to reprogram macrophage phenotypes, thereby enhancing antitumor immunity. By integrating insights from microbiology, immunology, and oncology, this article aims to provide a comprehensive overview of the microbiota’s impact on macrophage dynamics in cancer, paving the way for innovative therapeutic strategies that harness this relationship for improved clinical outcomes.

25 June 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HCHetty E. Carraway
Hetty E. Carraway
SMSridhar A. Malkaram
Sridhar A. Malkaram
YCYana Cen
Yana Cen
ASAymen Shatnawi
Aymen Shatnawi
JFJun Fan
Jun Fan
Tamer FandyTamer Fandy
Tamer Fandy
The FDA-approved DNA hypomethylating agents (DHAs) like 5-azacytidine (5AC) and decitabine (DAC) demonstrate efficacy in the treatment of hematologic malignancies. Despite previous reports that showed histone acetylation changes upon using these agents, the exact mechanism underpinning these changes is unknown. In this study, we investigated the relative potency of the nucleoside analogs and non-nucleoside analogs DHAs on DNA methylation reversal using DNA pyrosequencing. Additionally, we screened their effect on the enzymatic activity of the histone deacetylase sirtuin family (SIRT1, SIRT2, SIRT3, SIRT5 and SIRT6) using both recombinant enzymes and nuclear lysates from leukemia cells. The nucleoside analogs (DAC, 5AC and zebularine) were the most potent DHAs and increased the enzymatic activity of SIRT6 without showing any significant increase in other sirtuin isoforms. ChIP-Seq analysis of bone marrow cells derived from six acute myeloid leukemia (AML) patients and treated with the nucleoside analog DAC induced genome-wide acetylation changes in H3K9, the physiological substrate for SIRT6. Data pooling from the six patients showed significant acetylation changes in 187 gene loci at different chromosomal regions including promoters, coding exons, introns and distal intergenic regions. Signaling pathway analysis showed that H3K9 acetylation changes are linked to AML-relevant signaling pathways like EGF/EGFR and Wnt/Hedgehog/Notch. To our knowledge, this is the first report to identify the nucleoside analogs DHAs as activators of SIRT6. Our findings provide a rationale against the combination of the nucleoside analogs DHAs with SIRT6 inhibitors or chemotherapeutic agents in AML due to the role of SIRT6 in maintaining genome integrity and DNA repair.

2 October 2016 in Epigenetics
Verified
Journal Article
Open access
HHHazem E. Hassan
Hazem E. Hassan
JKJean-Arnaud Keita
Jean-Arnaud Keita
LNLawrence Narayan
Lawrence Narayan
SBSean M. Brady
Sean M. Brady
RFRichard Frederick
Richard Frederick
Tamer FandyTamer Fandy
Tamer Fandy
Curcumin and its analogs exhibited antileukemic activity either as single agent or in combination therapy. Dimethoxycurcumin (DMC) is a more metabolically stable curcumin analog that was shown to induce the expression of promoter-methylated genes without reversing DNA methylation. Accordingly, co-treatment with DMC and DNA methyltransferase (DNMT) inhibitors could hypothetically enhance the re-expression of promoter-methylated tumor suppressor genes. In this study, we investigated the cytotoxic effects and epigenetic changes associated with the combination of DMC and the DNMT inhibitor decitabine (DAC) in primary leukemia samples and cell lines. The combination demonstrated antagonistic cytotoxic effects and was minimally cytotoxic to primary leukemia cells. The combination did not affect the metabolic stability of DMC. Although the combination enhanced the downregulation of nuclear DNMT proteins, the hypomethylating activity of the combination was not increased significantly compared to DAC alone. On the other hand, the combination significantly increased H3K27 acetylation (H3K27Ac) compared to the single agents near the promoter region of promoter-methylated genes. Furthermore, sequential chromatin immunoprecipitation (ChIP) and DNA pyrosequencing of the chromatin-enriched H3K27Ac did not show any significant decrease in DNA methylation compared to other regions. Consequently, the enhanced induction of promoter-methylated genes by the combination compared to DAC alone is mediated by a mechanism that involves increased histone acetylation and not through potentiation of the DNA hypomethylating activity of DAC. Collectively, our results provide the mechanistic basis for further characterization of this combination in leukemia animal models and early phase clinical trials.